Security Class Suspension from Quotation
Filed with ASX · · 1 page · English
Earlier from OncoSil Medical
- Appendix 4D and Half Year Accounts
- CEO Remuneration Update
- Capital Raising Presentation
- Prospectus
- $8.0 million Capital Raise for Ongoing Commercial Expansion
Later from OncoSil Medical
- Security Class Reinstatement to Quotation - OSLOE
- OncoSil Medical Receives TGA Approval in Australia
- OncoSil progresses HDE with US FDA
- OncoSil Selected for Major European Pancreatic Cancer Study
- OncoSil Medical Files for FDA Approval
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical